Infectious diseases

#Infectious diseases

Liverpool spinout launches to support diagnostic innovation 

Liverpool School of Tropical Medicine (LSTM) has launched a spinout, iiDiagnostics, to enable industry engagement and commercial access to the world-leading diagnostics R&D capability and facilities at LSTM – supporting the discovery and development of innovative diagnostics with the aim of saving lives globally.  First steps … Read More

#News

#Collaboration #Infectious diseases #Public health

European Clinical Research Alliance for Infectious Diseases created 

In January 2022, European Clinical Research Alliance for Infectious Diseases (Ecraid) became a legal entity and is now fully operational to advance knowledge in the field of infectious diseases. This is Ecraid’s initial step as it evolves into a self-sustaining, not-for-profit organisation conducting clinical research for both public and… Read More

#News

#Drug discovery #Infectious diseases #Molecular Biology #Research

Researchers discover way to disarm potentially deadly Listeria bacteria 

University of Queensland researchers have discovered a way to block Listeria from making the proteins that allow bacteria to survive and multiply in immune cells, which can cause severe illness in pregnant women and people with compromised immune systems. The study has been published in the journal PLOS Pathogens. Read More

#News

#Infectious diseases #Microbiome

Microba Life Sciences receive landmark accreditation for Australia 

Microba technology has been used for microbiome analysis to unlock diagnostic applications. This has led to the company receiving ISO15189 accreditation for a new untargeted NGS based assay of stool samples. This makes the company the first Australian microbiome company granted ISO15189 accreditation by NATA (The National Association of Testing… Read More

#News

#Biotechnology #Cancer research #Funding #Infectious diseases

SpyBiotech announces VP appointment and expansion of scientific team 

SpyBiotech, a biotechnology company with a vaccine platform technology targeting infectious diseases, cancer and chronic diseases, has appointed Simon Jones as VP of Finance and Operations, and expanded its scientific team with four new hires.   Jones takes up the permanent position from Vien Phan, who held the… Read More

#News

#Biology #Drug development #Infectious diseases #MPS technology #Novel therapeutics #Organ-on-a-chip #Toxicology

Hype or hope – microphysiological systems?

Listen to this article on the DDW Podcast: Dr Tomasz Kostrzewski, Director of Biology at CN Bio Innovations, examines MPS in drug discovery as part of a preclinical toolbox.  Drug development remains slow and costly for the pharmaceutical industry, driven by the financial impact of late-stage failures of drug candidates1. Although… Read More

#Exclusive Content #Opinion #Trends & Analysis

#Infectious diseases #Precision medicine

Achieving the highest level of precision and safety 

Vaccination is the most effective method of preventing infectious diseases, and is considered one of the greatest achievements in medicine. This brochure, released by Sartorius, is designed to demonstrate precision and safety at its finest.   Until today, various vaccines against several crucial diseases (including influenza,… Read More

#News

#Clinical trials #Drug development #Drug discovery #Infectious diseases #Research

This week in drug discovery (9-13 August)

News round-up by DDW’s Megan Thomas for 9-13 August This week, DDW’s Megan Thomas has rounded up five stories which report positive data and findings from around the globe in the drug discovery sector. Preclinical data on oral polymer-based duodenal exclusion therapy Glyscend has presented data during the American… Read More

#News #Trending News

#Clinical trials #Drug development #Drug discovery #Infectious diseases #mRNA #Novel therapeutics #Oncology #Research

This week in drug discovery (2-6 August)

News round-up by DDW’s Megan Thomas for 2-6 August This week has seen results released, research continued, and clinical trial phases completed. DDW’s Megan Thomas has rounded up her top five stories showing promise in the drug discovery industry. Cardiac patients receiving nasal gel showed reduction of S. aureus… Read More

#News #Trending News

#Cancer research #Immunotherapy #Infectious diseases #RNA

eTheRNA immunotherapies opens new office

eTheRNA immunotherapies, a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, has opened a subsidiary, eTheRNA Asia, with offices located in the Sheung Wan area of Hong Kong. The Asia-Pacific region is growing in importance in the global healthcare sector and this new subsidiary will… Read More

#News

#Drug development #Infectious diseases #Life sciences #Precision medicine #Research

Cerba Research awarded NIH contract for lab services

Cerba Research has been awarded a five-year contract for Clinical Central Laboratory Services from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH). Findings from this research are said to be vital to NIAID’s efforts to advance vaccines, drugs, and diagnostic… Read More

#News

#Drug development #Drug discovery #Immuno-oncology #Infectious diseases #Neurodegenerative disorders

This week in drug discovery (26-29 July)

News round-up by DDW’s Megan Thomas for 26-19 July DDW’s Megan Thomas rounds up her top five stories this week which show how innovation in drug discovery is enhanced by collaboration, be it financial backing or through the combining of differing expertise to achieve a common goal. SARS-CoV-2 spike… Read More

#News #Trending News

#Antimicrobials #Drug development #Drug discovery #Infectious diseases #R&D

£1.9 million to combat infectious disease and antimicrobial resistance

The Bloomsbury SET, a knowledge exchange programme led by The Royal Veterinary College (RVC), has been awarded £1.9 million from Research England. Beginning in July 2021, the year-long project aims to commercialise research into infectious disease and antimicrobial resistance. Building on the current work of The Bloomsbury SET, this new… Read More

#News

#Covid-19 #Genomics #Infectious diseases #Therapeutics

Genomics analysis on why Covid-19 affects people so differently

Last year scientists from around the world undertook genetic analysis to uncover the genetic factors influencing why some Covid-19 patients develop severe, life-threatening disease requiring hospitalisation, while others escape with mild symptoms or none at all. A comprehensive summary of their findings to date, published in Nature, reveals 13 loci,… Read More

#Covid-19 #News #Trending News

#HIV #Immunology #Infectious diseases #Oncology #Pharmaceuticals

New GSK to deliver step-change in growth and performance

GlaxoSmithKline has announced New GSK, which will deliver step-change in growth and performance over next ten years, driven by a high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline. New GSK will keep a 20% stake in the consumer healthcare business. The Independent confirmed: “The unit will be listed on… Read More

#News

#Drug discovery #Infectious diseases #Life sciences #Research

Millions invested to help life sciences fight infectious disease

The UK’s centre for therapeutics innovation, Medicines Discovery Catapult (MDC), has received a £5 million grant to build a Translational Research Facility in Infectious Disease on its Alderley Park site, as part of the government’s Getting Building Fund programme. Actively seeking collaborations with SMEs, academics and others in infectious disease… Read More

#News